80 related articles for article (PubMed ID: 32826307)
41. Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England.
Amin-Chowdhury Z; Aiano F; Mensah A; Sheppard CL; Litt D; Fry NK; Andrews N; Ramsay ME; Ladhani SN
Clin Infect Dis; 2021 Mar; 72(5):e65-e75. PubMed ID: 33196783
[TBL] [Abstract][Full Text] [Related]
42. Liver infection and COVID-19: the electron microscopy proof and revision of the literature.
Pirisi M; Rigamonti C; D'Alfonso S; Nebuloni M; Fanni D; Gerosa C; Orrù G; Venanzi Rullo E; Pavone P; Faa G; Saba L; Boldorini R
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):2146-2151. PubMed ID: 33660834
[TBL] [Abstract][Full Text] [Related]
43. SARS-CoV-2 in first trimester pregnancy: a cohort study.
la Cour Freiesleben N; Egerup P; Hviid KVR; Severinsen ER; Kolte AM; Westergaard D; Fich Olsen L; Prætorius L; Zedeler A; Christiansen AH; Nielsen JR; Bang D; Berntsen S; Ollé-López J; Ingham A; Bello-Rodríguez J; Storm DM; Ethelberg-Findsen J; Hoffmann ER; Wilken-Jensen C; Jørgensen FS; Westh H; Jørgensen HL; Nielsen HS
Hum Reprod; 2021 Jan; 36(1):40-47. PubMed ID: 33145598
[TBL] [Abstract][Full Text] [Related]
44. Primary biliary cholangitis associated with SARS-CoV-2 infection.
Bartoli A; Gitto S; Sighinolfi P; Cursaro C; Andreone P
J Hepatol; 2021 May; 74(5):1245-1246. PubMed ID: 33610679
[No Abstract] [Full Text] [Related]
45. Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 and Hepatitis B Virus Co-infection.
Chen X; Jiang Q; Ma Z; Ling J; Hu W; Cao Q; Mo P; Yao L; Yang R; Gao S; Gui X; Hou W; Xiong Y; Li J; Zhang Y
Virol Sin; 2020 Dec; 35(6):842-845. PubMed ID: 32839868
[No Abstract] [Full Text] [Related]
46. COVID-19-related thrombotic microangiopathy in a cirrhotic patient.
Airoldi A; Perricone G; De Nicola S; Molisano C; Tarsia P; Belli LS
Dig Liver Dis; 2020 Sep; 52(9):946. PubMed ID: 32641274
[No Abstract] [Full Text] [Related]
47. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
48. Reactivation of SARS-CoV-2 infection following recovery from COVID-19.
Chen Z; Xie W; Ge Z; Wang Y; Zhao H; Wang J; Xu Y; Zhang W; Song M; Cui S; Wang X; Pan CQ
J Infect Public Health; 2021 May; 14(5):620-627. PubMed ID: 33848891
[TBL] [Abstract][Full Text] [Related]
49. Digestive health in Europe - lack of concerted action, exposed by COVID-19, starts with lack of uniform data reporting in liver disease.
Peck-Radosavljevic M
Infect Dis (Lond); 2020 Nov; 52(11):828-829. PubMed ID: 32838615
[No Abstract] [Full Text] [Related]
50. Manifestations of blood coagulation and its relation to clinical outcomes in severe COVID-19 patients: Retrospective analysis.
Zhang Y; He L; Chen H; Lu S; Xiong Y; Liu J; Zheng Y; Wang S; Liu L
Int J Lab Hematol; 2020 Dec; 42(6):766-772. PubMed ID: 32592539
[TBL] [Abstract][Full Text] [Related]
51. Letter: liver involvement and mortality in COVID-19-the role of anti-viral therapy should be considered.
Boglione L; Rostagno R; Poletti F; Moglia R; Bianchi B; Esposito M; Biffi S; Borrè S
Aliment Pharmacol Ther; 2021 Mar; 53(5):679-680. PubMed ID: 33566402
[No Abstract] [Full Text] [Related]
52. Comparison of RNA In Situ Hybridization and Immunohistochemistry Techniques for the Detection and Localization of SARS-CoV-2 in Human Tissues.
Massoth LR; Desai N; Szabolcs A; Harris CK; Neyaz A; Crotty R; Chebib I; Rivera MN; Sholl LM; Stone JR; Ting DT; Deshpande V
Am J Surg Pathol; 2021 Jan; 45(1):14-24. PubMed ID: 32826529
[TBL] [Abstract][Full Text] [Related]
53. Characteristics and in-hospital outcomes of COVID-19 patients with abnormal liver biochemical tests.
Wu Y; Ma Z; Guo X; Li H; Tang Y; Meng H; Yu H; Peng C; Chu G; Wang X; Teng Y; Zhang Q; Zhu T; Wang B; Tong Z; Feng R; Zhao H; Lu H; Qi X
Ann Hepatol; 2021; 24():100349. PubMed ID: 33862291
[No Abstract] [Full Text] [Related]
54. Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data.
Wang Y; Hu M; Yang H
J Hepatol; 2023 Jan; 78(1):e28-e31. PubMed ID: 36179997
[No Abstract] [Full Text] [Related]
55. COVID-19 + Cirrhosis = Excess Hospital Confinement, Excess Casualties.
Gonzalez HC; Trudeau S
Dig Dis Sci; 2023 Dec; 68(12):4290-4291. PubMed ID: 37864740
[No Abstract] [Full Text] [Related]
56. Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions-Review of the Literature.
Bucurica S; Ionita Radu F; Bucurica A; Socol C; Prodan I; Tudor I; Sirbu CA; Plesa FC; Jinga M
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676691
[TBL] [Abstract][Full Text] [Related]
57. COVID-19 in patients with cirrhosis: understanding adverse impact.
Sharma S; Elhence A; Vaishnav M; Kumar R; Shalimar
Gut; 2021 Jul; 70(7):1409. PubMed ID: 32826307
[No Abstract] [Full Text] [Related]
58. Liver fibrosis and adverse outcomes in COVID-19.
Huang J
Dig Liver Dis; 2021 Jul; 53(7):799. PubMed ID: 33994131
[No Abstract] [Full Text] [Related]
59. SARS-CoV-2 infection in patients with a normal or abnormal liver.
Cabibbo G; Rizzo GEM; Stornello C; Craxì A
J Viral Hepat; 2021 Jan; 28(1):4-11. PubMed ID: 33190321
[TBL] [Abstract][Full Text] [Related]
60. The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research.
Gao F; Huang ZM
J Hepatol; 2020 Dec; 73(6):1568-1569. PubMed ID: 32574579
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
